Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Like other peptides sold on Breckas website, the ipamorelin vials carry the labeling: research use only. Research claims are often a ploy to dodge regulators The research use language is pervasive across the peptide space, even in forums where users trade tips for buying, dosing and stacking different drug combinations
11 Journal of Investigative DermatologyThymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue
Your healthcare team will develop an individualised management plan based on investigation findings and clinical context
Category 1 status only means a substance is eligible for use by 503A compounding pharmacies pending final FDA rulemaking
Potential Benefits: IBD mouse models show reduced colitis scores May support chronic inflammatory skin diseases Localized gut-immune modulation Suggested Clinical Dosing Range: 200500 mcg subcutaneous or oral Dosing is individualized and determined by a qualified medical provider
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
US$ 24.31
US$ 24.86
US$ 26.38
US$ 29.38
US$ 28.93
US$ 22.19
